Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.

Background: Serum S100B and LDH, as well as the status of the sentinel node, have been reported as prognostic markers in melanoma patients. The purpose of this study was to determine the value of serum S-100B and LDH in melanoma patients prior to sentinel lymph node dissection (SLND) with respect to the clinical outcome.

Patients And Methods: Serum S100B and LDH were measured prior to SLND in 259 melanoma patients between 2000 and 2006.

Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm.

The histopathologic status of the sentinel node (SN) and the ulceration of the primary tumor are important indicators of the clinical outcome of melanoma patients. The purpose of this study was to investigate potential correlations between prognostic factors and the sentinel lymph node status as well as their influence on disease-free survival (DFS), distant metastases-free survival (DMFS), and overall survival (OS). The medical records of 259 melanoma patients who underwent sentinel lymph node dissection between 2000 and 2006 were analyzed.